Literature DB >> 10632343

Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.

C Pfister1, L Moore, P Allard, H Larue, L Lacombe, B Têtu, F Meyer, Y Fradet.   

Abstract

The aim of the study was to determine whether the expression of the cell cycle markers p53, MDM2, p21, and Ki-67 was predictive of superficial bladder cancer recurrence and to compare the relative predictive power for tumor recurrence of a cell cycle index based on the number of abnormally expressed cell cycle markers with a clinicopathological index based on primary clinical tumor characteristics. The expression of p53, MDM2, and p21 proteins and the value of the Ki-67 index were analyzed for 244 patients. One hundred ninety-four lesions were determined to be superficial papillary tumors (pTa), whereas 50 tumors invaded the lamina propria (pT1). Tumor grade was noted low (grade 1) in 83 cases and high (grades 2-3) in 161 cases. An avidin-biotin peroxidase method was performed using monoclonal antibodies against p53, MDM2, p21, and Ki-67 antigens after antigen retrieval treatment of formalin-fixed specimens. The cell cycle marker index was created using the number of abnormally expressed cell cycle markers according to the following cutoff points: p53 (>5%), MDM2 (>20%), p21 (<5%), and Ki-67 (>10%). The clinicopathological index was created using the following adverse tumor characteristics: grades G2-G3, stage pT1, multifocality, and diameter of tumors > 3 cm. Cox regression models were used to calculate the relative risks and their 95% confidence intervals associated with disease recurrence for the clinicopathological index and the cell cycle marker index. The chi2 test was performed to describe the correlation between the Ki-67 index and p53, MDM2, and p21 protein expression. Kaplan-Meier survival curves were generated to demonstrate the disease-free survival according to these two prognostic indexes. The clinicopathological index was a strong, independent predictor of disease recurrence where tumors with three or four adverse tumor characteristics at initial resection had over four times the risk of recurrence than tumors with no risk factors (P for trend = 0.0001). A strong correlation was observed between the Ki-67 index >10% and both MDM2 and p21 proteins. MDM2 was overexpressed in 106 tumors (43%), and p53 was overexpressed in 47 (19%); Ki-67 was >10% in 171 cases (70%). Thirty-nine tumors (16%) were p21 negative. The risk of recurrence increased slightly with the number of abnormally expressed cell cycle markers, but when the clinicopathological index was taken into account in multivariate analysis, the cell cycle marker index was not predictive of disease recurrence (P for trend = 0.72). The cell cycle markers studied provided no added prognostic information on disease recurrence after initial resection of papillary superficial tumors when the clinicopathological parameters were taken into account.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10632343

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  14 in total

Review 1.  Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas.

Authors:  Christopher Y Thomas; Dan Theodorescu
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

2.  Role of tumor suppressor and angiogenesis markers in prediction of recurrence of non muscle invasive bladder cancer.

Authors:  Usha Agrawal; Ashwani K Mishra; Payal Salgia; Saurabh Verma; Nayan K Mohanty; Sunita Saxena
Journal:  Pathol Oncol Res       Date:  2010-06-23       Impact factor: 3.201

3.  Immunohistochemical expression of TGF-beta1, p21WAF1, p53, Ki67, and angiogenesis in gastric carcinomas: a clinicopathologic study.

Authors:  Vassiliki Zolota; Anna Batistatou; Athanassios C Tsamandas; George Iliopoulos; Chrisoula D Scopa; Dionysis S Bonikos
Journal:  Int J Gastrointest Cancer       Date:  2002

Review 4.  Molecular pathology of non-invasive urothelial carcinomas (part I).

Authors:  Burkhard Helpap; Bernd J Schmitz-Dräger; Peter W Hamilton; Giovanni Muzzonigro; Andrea B Galosi; Karl H Kurth; David Lubaroff; David J Waters; Michael J Droller
Journal:  Virchows Arch       Date:  2003-02-11       Impact factor: 4.064

5.  Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer.

Authors:  José M A Moreira; Gita Ohlsson; Pavel Gromov; Ronald Simon; Guido Sauter; Julio E Celis; Irina Gromova
Journal:  Mol Cell Proteomics       Date:  2009-09-25       Impact factor: 5.911

6.  GSTM1 tissue genotype as a recurrence predictor in non-muscle invasive bladder cancer.

Authors:  Yun-Sok Ha; Chunri Yan; Pildu Jeong; Won Tae Kim; Seok-Joong Yun; Isaac Yi Kim; Sung-Kwon Moon; Wun-Jae Kim
Journal:  J Korean Med Sci       Date:  2011-01-24       Impact factor: 2.153

7.  Spotlight on differentially expressed genes in urinary bladder cancer.

Authors:  Apostolos Zaravinos; George I Lambrou; Dimitrios Volanis; Dimitris Delakas; Demetrios A Spandidos
Journal:  PLoS One       Date:  2011-04-05       Impact factor: 3.240

8.  Association between AgNORs and Immunohistochemical Expression of ER, PR, HER2/neu, and p53 in Breast Carcinoma.

Authors:  Hussain Gadelkarim Ahmed; Mohammed Ali Al-Adhraei; Ibraheem M Ashankyty
Journal:  Patholog Res Int       Date:  2011-11-01

9.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12

10.  Tumor markers of bladder cancer: the schistosomal bladder tumors versus non-schistosomal bladder tumors.

Authors:  Ahmed S Abdulamir; Rand R Hafidh; Haider S Kadhim; Fatimah Abubakar
Journal:  J Exp Clin Cancer Res       Date:  2009-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.